CFT is a sensitive and early predictor of VA deterioration. Four letters of acute VA loss seems to be a critical limit. VA loss of ≥ 4 letters appears to be associated with incomplete recovery. Eyes with <1 line of gain at the end of the loading phase should be considered for continuation of treatment at months 3 and 4. According to our calculations an average number of 8.4 injections/eye seems to be necessary to maintain stabilization of vision in the first year of treatment.

Heavy brilliant blue G (BBG-D₂O) provides a significantly improved staining effect of the ILM and by this makes ILM peeling more efficient, easier, faster and less traumatic.

Macular edema after BRVO can effectively be treated by a combination of intravitreal TA injection and subsequent laser photocoagulation. During a 6-month follow-up this combination treatment resulted in a significant reduction of central foveal thickness and improvement of visual acuity.

The heterogeneity of available clinical data does not allow a definitive comparison of the 3 heavier-than-water endotampondes. The data so far available seem to indicate as a trend that Densiron 68 may provide advantages compared to other substances concerning the relative incidence of severe complications. On the background of relatively high rates of heavy silicone complications it seems reasonable to regard conventional "light" silicones as first choice if a silicone endotamponade is desired and no need for a gravity effect of the endotamponade is indicated.

Under optimized laboratory conditions the use of Lucentis injection sets results in a relatively bad controlled application of ranibizumab doses. Preloading of syringes to the level of the intended injection should be abandoned and substituted by a differential injection mode. It seems recommendable to use smaller syringes than those provided.